Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Clinical Study Evaluating the Efficacy and Safety of CID v2.2 in Glaucoma Surgery

NCT: NCT05625958 · ACTIVE_NOT_RECRUITING

NCT IDNCT05625958
StatusACTIVE_NOT_RECRUITING
Start Date2023-03-23
Completion2028-09-01

Brief Summary

The purpose of this study is to evaluate the safety and effectiveness of implanting a new version of an interposition supraciliary implant (SV22) as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open and narrow angle glaucoma who have failed at least one class of topical medical therapy

Frequently Asked Questions

What is Clinical Study Evaluating the Efficacy and Safety of CID v2.2 in Glaucoma Surgery?

Clinical Study Evaluating the Efficacy and Safety of CID v2.2 in Glaucoma Surgery is a clinical trial registered under NCT05625958. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05625958?

The current status of NCT05625958 (Clinical Study Evaluating the Efficacy and Safety of CID v2.2 in Glaucoma Surgery) is: ACTIVE_NOT_RECRUITING.

When did Clinical Study Evaluating the Efficacy and Safety of CID v2.2 in Glaucoma Surgery start?

Clinical Study Evaluating the Efficacy and Safety of CID v2.2 in Glaucoma Surgery started on 2023-03-23.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑